Hepion Pharmaceuticals Inc Total Liabilities
Hepion Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) has total liabilities worth $402.40K USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See HEPA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Hepion Pharmaceuticals Inc (2012–2025)
Total liabilities of Hepion Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Hepion Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Hepion Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Hepion Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Netmedia Group S.A.
PA:ALNMG
|
France | €19.40 Million |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
USA | $9.67 Million |
|
BrightBid Group AB (publ)
ST:PERP-B
|
USA | Skr30.44 Million |
|
Beeks Trading Corporation Ltd
LSE:BKS
|
UK | GBX14.48 Million |
|
Vertical Explorations Inc
V:VERT
|
Canada | CA$988.15K |
|
Smtrack Bhd
KLSE:0169
|
Malaysia | RM23.76 Million |
|
Current Water Technologies Inc
V:WATR
|
Canada | CA$1.66 Million |
|
FAT Brands Inc
NASDAQ:FATBB
|
USA | $1.80 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Hepion Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Hepion Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Hepion Pharmaceuticals Inc Total Liabilities Ratios Explained
Hepion Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hepion Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hepion Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Hepion Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $402.40K | -88.43% |
| 2024-12-31 | $3.48 Million | -67.85% |
| 2023-12-31 | $10.81 Million | +4.09% |
| 2022-12-31 | $10.39 Million | -1.60% |
| 2021-12-31 | $10.56 Million | +29.93% |
| 2020-12-31 | $8.12 Million | +62.66% |
| 2019-12-31 | $4.99 Million | -19.62% |
| 2018-12-31 | $6.21 Million | -17.69% |
| 2017-12-31 | $7.55 Million | -35.96% |
| 2016-12-31 | $11.79 Million | +508.28% |
| 2015-12-31 | $1.94 Million | -60.72% |
| 2014-12-31 | $4.93 Million | 0.00% |
| 2013-12-31 | $4.93 Million | +2071.59% |
| 2012-12-31 | $227.21K | -- |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more